© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Discovery stories like that of 11Α,17Α-Dihydroxyprogesterone showcase the sheer will and curiosity behind hormone research. Researchers in the mid-20th century recognized that tweaking the traditional progesterone molecule brought functions they hadn’t imagined. By exploring plant sources and bovine brains, chemists unlocked 11Α,17Α-Dihydroxyprogesterone, and much of the early synthesis work owed thanks to improvements in chromatography and steroid chemistry. By the 1970s, scientists in both academic and pharmaceutical labs knew they could shape progestogens to influence cell signaling more directly, with fewer androgenic side effects. Driven by demand for contraceptives, hormone therapies, and diagnostic agents, development continued steadily, especially as steroidal chemistry gave new control over metabolism and bioactivity.
11Α,17Α-Dihydroxyprogesterone stands as a classic intermediate in steroid chemistry, often popping up in the supply chain behind prescription drugs. Its structure, similar to natural progesterone, carries extra hydroxyl groups at the 11 and 17 alpha positions. Drug makers rely on these features because small shifts in molecular structure help control how the body processes steroids. It’s often supplied as a white to pale yellow powder, stable under standard laboratory conditions and handled in tightly sealed containers to prevent exposure to light and humidity.
When chemists handle 11Α,17Α-Dihydroxyprogesterone, they work with a solid melting somewhere around 200–220°C, and a molecular weight in the ballpark of 346 g/mol. Water won’t dissolve it well, but organic solvents like chloroform, acetone, or ethanol usually do the trick. The two hydroxyls on the D ring change not just the polarity, but also the way it fits into enzyme active sites, making it a key intermediate in corticosteroid manufacture. Infrared and NMR spectra tell trained eyes about the unique arrangement of its functional groups, allowing researchers to confirm synthetic success.
Labs and manufacturers packaging 11Α,17Α-Dihydroxyprogesterone often provide purity above 97%, with specific data sheets laying out moisture content, melting range, and residual solvents. Labels follow international standards—batch number, expiration, storage temperature, and safety warnings in clear typeface. Lot documentation includes testing records, and adherence to Good Manufacturing Practice (GMP) means each shipment gets traceability from raw material to processed powder. Some suppliers also add spectroscopic fingerprints and include recommended handling guidelines to minimize occupational exposure.
Synthesizing 11Α,17Α-Dihydroxyprogesterone typically begins with common plant steroids, especially diosgenin from wild yams or solasodine from nightshades. Laboratories carry out protection and functionalization steps—think hydrolysis, selective oxidation, then careful reduction—to position the hydroxyls just right on the steroid backbone. These steps take time, experience, and a sharp eye for reaction conditions, as any side reactions can damage yields. Purification, including crystallization and chromatography, ensures that by the time product hits the scale, it fits tight chemical criteria. Evolving green chemistry is now steering synthesis away from heavy metals in reagents and lowering hazardous waste.
11Α,17Α-Dihydroxyprogesterone acts as a valuable synthetic pivot. From here, researchers launch into esterification, acetylation, and oxidation, creating more elaborate corticosteroids for clinical trials and commercial supply. Medicinal chemists react its hydroxyls with anhydrides or acyl chlorides, looking for new derivatives with better uptake or reduced breakdown in the body. The double bonds and ketone at C-3 allow further tweaking, which tailors potency or selectivity for receptor targets. Analytical checks—TLC, HPLC, and mass spectrometry—guide reaction success, while keeping a sharp watch for impurities.
In lab catalogs, 11Α,17Α-Dihydroxyprogesterone adopts a half-dozen references. Scientists recognize it by names such as 11α,17α-Dihydroxyprogesterone or by related identifiers in the CAS database. Other synonyms include 11,17-Dihydroxy-4-pregnene-3,20-dione, and sometimes it pops up in trade under manufacturer-specific codes. Researchers and customs officers check both IUPAC names and shorter labels, which helps avoid confusion during shipping and regulatory filing. Identifying synonyms also helps in literature searches, connecting older research to present work.
People handling 11Α,17Α-Dihydroxyprogesterone in labs or manufacturing plants put safety first. Standard operating procedures call for gloves and goggles, wearing dust masks when transferring the powder into reactors or sample containers. Workers keep the material away from open flames or oxidizers, not just for fire risk, but also to avoid generating hazardous byproducts. Eye-wash stations and fume hoods sit close by, along with spill control kits. Routine training keeps new employees mindful of exposure symptoms and emergency protocols. Sites document disposal steps for waste, often using incineration for any contaminated solids, protecting the water supply and air quality.
The main field for 11Α,17Α-Dihydroxyprogesterone runs through pharmaceuticals. Drug developers use it as a building block when crafting anti-inflammatory medicines and synthetic hormones. Some products in dermatology, immunosuppression, and asthma therapy trace their roots back to this exact compound. Animal researchers and endocrinologists value its role in deciphering adrenal cortex function. Technical specialists in analytical chemistry also depend on its reactivity and purity to serve as a reference standard in bioassays or calibrators for advanced equipment, giving reliable readouts in clinical research.
Every new batch of 11Α,17Α-Dihydroxyprogesterone advances the quest for safer, more effective treatments. Scientists push boundaries—modifying its structure, mapping biotransformation in the body, and searching for new targets in inflammation and cancer. New tools in mass spectrometry and X-ray crystallography unravel how it binds to proteins, while cell biology teams track downstream genes it activates. Industrial research groups scale up synthesis under more sustainable conditions, aiming for higher yield and less waste. Collaborations between academic teams and manufacturers push for regulatory clarity and better standards for characterization, which smooths the pathway for future medicines.
Toxicologists and pharmacologists dig deep into 11Α,17Α-Dihydroxyprogesterone’s effects on living systems. They dose animals and observe for short and long-term side effects: impact on reproduction, immune system function, and metabolic balance. For most intended clinical uses, the risks center on hormone-driven changes—altered blood pressure, sodium retention, shifts in mood or behavior. Chronic exposure studies unearth what repeated exposure may cause, to safeguard workers and patients. Careful recording, statistical review, and open data sharing help flag potential dangers before advancing to market.
The outlook on 11Α,17Α-Dihydroxyprogesterone tracks with wider shifts in steroid medicine. Researchers hunt for new derivatives with fewer complications—lowering risk of blood clots or bone loss. Advances in enzyme engineering hint at biocatalysts that clean up synthesis, opening routes to molecules nature never built. As pressure grows for green chemistry, new methods keep hazardous waste down and protect workers. Rapid regulatory shifts also demand more transparent safety data and improved labeling. Whether deployed in classic hormone therapy or as a launch point for next-generation drugs, the compound’s role as a chemical workhorse stands firm, promising more options for chronic disease and acute care in the years to come.
11Α,17Α-Dihydroxyprogesterone might sound intimidating, but its role touches real lives every day. This compound sits within the group of steroids that mimic or alter our natural hormones. In the world of medicine, these lab-made hormones serve as the backbone for a whole class of treatments. I’ve seen plenty of medical science marathons chasing safer and more effective drugs, and learning about the part 11Α,17Α-Dihydroxyprogesterone plays in those efforts can clear up some of the confusion often stirred by scientific names.
The medical field always looks for ways to nudge the body's hormones into balance, especially for people facing issues with their adrenal glands or reproductive systems. 11Α,17Α-Dihydroxyprogesterone steps in as a foundation, a key building block in making other corticosteroids. Medications inspired by this compound often target problems like Addison's disease, where the adrenal glands no longer make enough essential steroids.
Having spent years talking to pharmacists and endocrinologists, I’ve come to appreciate how these steroid-based drugs change patient outcomes. For someone with hormone shortages or problems like congenital adrenal hyperplasia, doctors turn to molecules similar to 11Α,17Α-Dihydroxyprogesterone to restore normal function, cut the risk of dangerous inflammation, and help patients take back control over their health.
Beyond pure hormone replacement, similar compounds find a use in treating inflammatory conditions. Medical teams shape related steroids to battle arthritis flare-ups, allergic reactions, and some cancers. Scientists have also investigated these structures as starting points for dermatological drugs, which opens up skin treatments for rashes or eczema that don’t respond to standard creams.
In the pharmaceutical lab, 11Α,17Α-Dihydroxyprogesterone stands as a versatile molecule. Creating reliable, safe drugs demands precise chemistry – shaping molecules that fit the body’s own hormone “locks.” Even a tiny tweak can shift a drug's safety or usefulness for someone taking it daily for chronic health problems.
Not all patients handle steroid treatments the same way. Long-term use brings its own hurdles, including weight gain, blood sugar spikes, and bone thinning. This is where careful dosing and supervision count. No one wants their treatment to fix one problem and stir up three more. I’ve spoken with people who feel caught between relief and rough side effects – it’s a constant reminder that drug development needs people-centered thinking, not just chemistry knowledge.
Doctors need more than a basic understanding of these molecules. Up-to-date labs and training matter, too. Some clinics lack the resources to monitor complex treatments, especially in rural or underserved spots. This gap can widen health disparities, leaving some families with poorer outcomes through no fault of their own. Professional groups including the Endocrine Society recommend that any new drug or treatment involving synthetic steroids like this one gets thorough review in long-term studies.
Improving access to diagnostic tools and more precise hormone tests could help patients start on the right dose and avoid complications. Teamwork between pharmacists, doctors, and patient groups can spark new solutions. With a focus on practical education and transparency about risks and benefits, both professionals and patients stand a better chance at positive experiences.
Supporting research into refined steroid drugs—ones that keep benefits high but side effects lower—could make a big difference. Programs that bring clinical trials to community hospitals might offer some fresh answers for the patients behind the science, giving real people safer and more flexible treatment options in the future.
11Α,17Α-Dihydroxyprogesterone doesn’t often end up in popular health news, yet interest around it grows among researchers in hormone therapy and endocrinology. I remember the time I first heard about analogues of progesterone in a medical seminar. There’s excitement about what these compounds can do, but also wariness—experience with steroid hormones teaches us always to check for side effects before getting too optimistic.
This compound builds off the progesterone backbone and tweaks it, affecting the way it behaves in the body. Progesterone itself is central to female reproductive health and influences several other body functions in men and women alike. When molecules play in that hormonal sandbox, they often bring benefits—and baggage.
Anyone familiar with steroid hormone analogues knows the body reacts in patterns. People using substances like 11Α,17Α-dihydroxyprogesterone may experience shifts in mood, sometimes anxiety or mild depression. I’ve heard from folks who notice irregular cycles, spotting, or sudden changes in bleeding—effects seen with other progestins too. For anyone who values stability, these can quickly become disruptive.
It’s easy to overlook weight changes, but they crop up in conversations just as often. Fluid retention, bloating, and tenderness in breasts all stem from hormone shifts at the receptor level. It’s not always dangerous, but it gets uncomfortable fast.
There are side effects that demand more attention: signs of liver stress, headaches that don’t quit, skin rashes, or even allergic reactions. One case that sticks in my mind involved persistent headaches linked to hormonal treatments—the kind that sideline work and life for days at a time. Any signal like jaundice or right-sided abdominal pain needs attention from a doctor, not just a home remedy.
Long-term use of any strong hormone can affect cholesterol metabolism. Some studies with related compounds show a rise in LDL, a drop in HDL, or both. Over the years, these changes increase heart disease risk, something that doesn’t show up right away but builds over time. Keeping regular tabs on cholesterol always made sense to me, especially for those with a family history of heart issues.
Mental health often takes a hit—more than people expect. Mood swings, irritability, even spells of depressive thinking turn up in conversations. Hormones shape more than just the reproductive system; they reach into the brain, guiding neurotransmitters and sometimes throwing off a person’s sense of well-being. I’ve seen patients frustrated by a change they couldn’t quite describe until their doctor linked it back to the therapy.
All the new treatments in endocrinology need careful oversight. Screening before starting therapy reduces surprises. Regular blood work, especially liver panels and cholesterol, keeps things in check. Sharing concerns early with a healthcare provider helps catch rare reactions before they spiral. I always encourage people to jot down any new symptom, big or small—tracking patterns makes it easier to spot a connection with treatment.
Health professionals continue to push for safer versions of these compounds with fewer side effects. If 11Α,17Α-dihydroxyprogesterone plays a bigger role in the future, honest conversations about risk will need to keep pace with the science.
11Α,17Α-Dihydroxyprogesterone sounds complicated, but it’s basically a hormone derivative that comes up quite a bit in endocrinology and research. It’s part of a group of substances that help us understand steroid hormone pathways, and sometimes it acts as a key ingredient in making other drugs. Many folks working in specialized labs or clinics look at this chemical for its role in studying adrenal gland function, as well as its possible therapeutic uses for certain hormonal disorders.
I've seen a lot of confusion about how to give this compound safely and effectively. The most direct and reliable approach for 11Α,17Α-Dihydroxyprogesterone usually involves intramuscular injection. This method tends to deliver a consistent dose straight into the bloodstream, which helps keep hormone levels stable. Orally, the compound doesn't hold up so well. Stomach acids and first-pass liver metabolism can break down the hormone before it has much of a chance to do anything useful.
For those not comfortable with injections, transdermal creams and gels sometimes make sense. The skin can absorb certain hormones, and this method sidesteps the stomach issue. But absorption through the skin can vary a lot from person to person, depending on factors like thickness of the skin, temperature, and even sweat. Because of these variables, doctors always measure blood hormone levels during therapy.
In my time working with hormone therapies, the risks of DIY dosing always stand out. Hormones influence all sorts of body systems: weight, mood, heart health, even bones. With compounds like 11Α,17Α-Dihydroxyprogesterone, it’s easy to tip the balance too far. Overdosing or taking it at the wrong time can trigger everything from blood pressure changes to menstrual irregularities to irritability.
Qualified doctors run regular blood tests to stay on top of these side effects. They keep a close eye on other hormones like cortisol and testosterone, as they all link together. If something seems off, the dose changes or the delivery method switches. Getting these hormones right brings big rewards — better energy, more stable mood, stable bone density. Getting it wrong can do a lot of harm.
Patients often talk about convenience. Injections can feel like a hassle, creams can stain clothing or leave residue, and daily pills don’t always deliver enough of the drug. I’ve heard from people frustrated by waiting rooms and the expense of regular monitoring, but skipping these steps leads to more problems in the long run.
Education matters. When folks know the symptoms that signal trouble — like abnormal bleeding, severe headaches, or depression — they call for help sooner. Clinics that build in counseling and transparency about side effects usually get better outcomes.
Pharmacies that source medical-grade 11Α,17Α-Dihydroxyprogesterone help reduce the risk of impurities. Doctors familiar with hormone therapy protocols — the ones who teach about food interactions, injection technique, and monitoring schedules — hold the key to safer, more effective treatment. For anyone considering this therapy, working with a collaborative team brings not just safety, but peace of mind.
Questions about prescriptions don’t usually pop up unless a product comes with some baggage. 11Α,17Α-Dihydroxyprogesterone has earned attention mostly because it sits in the larger family of steroid hormones. Doctors use it and its cousins as stepping stones in the creation of treatments for things like hormone imbalances, fertility issues, and certain forms of cancer. Walk into any pharmacy and try to pick up a hormone product without talking to a medical professional, and you’ll run into a brick wall. The regulations draw a pretty clear line: this kind of compound usually anchors a prescription-only class of medication.
The effects of hormones in the body play out loud and fast. They oversee reproductive cycles, influence mood, and even shape how other glands react. When using synthetic or semi-synthetic options such as 11Α,17Α-Dihydroxyprogesterone, it isn’t just about tackling symptoms. Too much of the wrong signal can spark headaches, blood clots, liver swirl, or all sorts of chaos for folks with vulnerable health backgrounds. Stories from the world of unregulated supplements show how fast things can spin out of control if people self-dose or source products online without a doctor’s input. Some have ended up back in clinics with problems far worse than they started with. That’s a mighty lesson — and a main reason laws keep these products behind the pharmacy counter.
Just about every country treats this group of substances with care. Health authorities in the United States, Canada, the UK, Australia, and across Europe need a prescription from a licensed medical provider before anyone hands over products containing hormones like 11Α,17Α-Dihydroxyprogesterone. No pharmacist will gamble their license on a shortcut. In my own talks with community pharmacists, they talk about strict logs, regular audits, and training sessions focused on keeping hormone sales above board. For rare, research-use-only settings, suppliers might fill orders but always keep paperwork neat and demand proof that buyers hold professional credentials. Nobody takes risks here because the fallout isn’t worth it.
Online black markets or questionable “wellness” shops paint a tempting picture. The price looks good, questions are few, and shipping sounds quick. Yet that friendly facade hides dangers. A World Health Organization study found that up to 50% of drugs sold online last year dodged quality checks. Faulty or fake ingredients, improper doses, and zero aftercare turned simple hormone purchases into emergencies, with some users landing in ERs because of contaminated or mislabeled ingredients. Even seasoned athletes who thought they were just speeding up recovery found themselves wrapped up in investigation whirlwinds. No shortcut saves trouble in the end.
Doctors keep up to date on shifting formulas and side effect profiles. For anyone convinced they might need a compound like 11Α,17Α-Dihydroxyprogesterone, the best route runs through a health care provider. They evaluate history, order labs, and explain which hormone is safe — or not — for your body. Pharmacists guide people through side effects, interact with main prescribers, and stop errors before harm sets in. That’s the kind of reliability nobody gets through an unregulated source. Following this path means fewer mysteries, better outcomes, and access to real help if things go sideways.
Banning a product sounds strict, but it blocks harm. More open information, ongoing public health education, and honest talks with health professionals build a stronger safety net. Clearer communication about what each hormone does lets people recognize both promise and risk. In my experience, people do better when they trust their clinicians, read up, and resist the urge to play doctor through online forums. Testosterone, progesterone, 11Α,17Α-Dihydroxyprogesterone: these are more than chemical names. They represent real stakes in health, and treating them that way keeps more people well in the long run.
Taking 11Α,17Α-Dihydroxyprogesterone, a synthetic hormone closely tied to progesterone, puts a person in a spot where drug interactions get personal, not just theoretical. Real people react in real ways. Women with a history of hormone-sensitive cancers face some of the strongest warnings because synthetic progestins can stoke cancer cell growth. If breast cancer crept into my own family history, I wouldn’t touch this hormone without a full conversation with a seasoned oncologist. Not every risk is about cancer, though. Some people have a tendency toward blood clots; they need extra caution, because progestins can tip the scale toward clot formation, just like regular birth control pills.
Mixing medicines always involves more than scanning a checklist. I’ve seen confusion set in around antibiotics like rifampin or even epilepsy drugs like phenytoin and carbamazepine. These drugs rev up liver enzymes. In reality, these enzymes chop down synthetic hormones faster. Anyone using these together risks losing the full benefit of hormone therapy—cycles can go off track, and contraception may fail. The other way around, strong hormone levels might actually build up when combined with drugs that slow down those same liver enzymes, raising side effects. Grapefruit juice, for example, changes enzyme activity enough to create uncomfortable surprises.
The health conditions people bring with them to the pharmacy counter change everything. Someone already fighting liver disease faces a steeper climb. Synthetic hormones get processed in the liver, so any weakness there raises the risk of hormone buildup. The story changes with kidney problems too; waste products stick around longer, triggering unintended hormone effects. Heart conditions set off another warning bell. Hormone therapies—even progestins—sometimes bring fluid retention, weight gain, or changes in blood pressure. I’ve noticed older folks or those with heart trouble wind up with swelling or new heart symptoms after starting hormonal drugs.
Every guideline stresses open talk with a reliable healthcare provider. I’ve seen people dodge problems by handing their doctor a full list of everything they use—prescriptions, vitamins, and even herbal teas. Some herbal supplements, like St. John’s Wort, lower hormone levels by speeding up metabolism. This can lead to missed periods, unexpected bleeding, and even pregnancy. Patients who skip sharing supplement use miss important information. A straightforward conversation serves as real prevention.
Routine blood work helps too. Looking at hormone levels in the blood can reveal if the drug works as planned or if there’s a silent clash with another medicine. Pharmacists serve as another set of eyes, flagging risky combinations before prescriptions are filled.
Sticking with up-to-date science and guidance matters. I look for sources like the FDA’s drug label, respected endocrinology groups, or trusted pharmacist advice to confirm whether it’s safe to start or keep taking 11Α,17Α-Dihydroxyprogesterone. Healthcare teams must keep sharing, correcting, and growing their information pools for medicines that overlap and interact so much.
Everyone involved—the person taking the medicine, the doctor, and the pharmacist—shares a job in catching problems before they start. This hormone isn’t just another pill; it demands a real look at the whole person and everything they use.
| Names | |
| Preferred IUPAC name | (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one |
| Other names |
11α,17α-Dihydroxy-4-pregnen-3,20-dione 11α,17α-Dihydroxyprogesterone |
| Pronunciation | /ˌɪl.ev.əˌænˌdɪ.haɪˌdrɒk.si.proʊˈdʒes.təˌroʊn/ |
| Identifiers | |
| CAS Number | 979-02-2 |
| 3D model (JSmol) | `3D structure; JSmol model string for 11α,17α-Dihydroxyprogesterone: "C1[C@@H]2C[C@@H]3[C@@H](CC2=CC4=CC(=O)CCC4(C3CCC1=O)C)O" ` |
| Beilstein Reference | 100332 |
| ChEBI | CHEBI:34638 |
| ChEMBL | CHEMBL1193257 |
| ChemSpider | 21559638 |
| DrugBank | DB01481 |
| ECHA InfoCard | 07e022f1-d3b4-4ef8-88c7-a2b9952eacb0 |
| EC Number | 1.1.1.209 |
| Gmelin Reference | 19146 |
| KEGG | C14781 |
| MeSH | D004362 |
| PubChem CID | 13938 |
| RTECS number | LU4375000 |
| UNII | 6A7F4PBW8H |
| UN number | UN2811 |
| CompTox Dashboard (EPA) | DTXSID90170997 |
| Properties | |
| Chemical formula | C21H30O4 |
| Molar mass | 344.471 g/mol |
| Appearance | White crystalline powder |
| Odor | Odorless |
| Density | 1.2 g/cm3 |
| Solubility in water | Slightly soluble in water |
| log P | 2.2 |
| Vapor pressure | 4.14E-10 mmHg at 25°C |
| Acidity (pKa) | 13.47 |
| Basicity (pKb) | 3.39 |
| Magnetic susceptibility (χ) | -1281.0e-6 cm^3/mol |
| Refractive index (nD) | 1.5820 |
| Viscosity | Oily liquid |
| Dipole moment | 3.25 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 321.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | –626.1 kJ·mol⁻¹ |
| Std enthalpy of combustion (ΔcH⦵298) | Std enthalpy of combustion (ΔcH⦵298) of 11Α,17Α-Dihydroxyprogesterone is -9586 kJ mol⁻¹ |
| Pharmacology | |
| ATC code | G03DA04 |
| Hazards | |
| Main hazards | Harmful if swallowed. Causes serious eye irritation. Causes skin irritation. May cause respiratory irritation. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | GHS06, GHS08 |
| Signal word | Warning |
| Hazard statements | H315, H319, H335 |
| Precautionary statements | P261, P264, P272, P280, P302+P352, P362+P364, P501 |
| Flash point | Flash point: 9.7 °C |
| LD50 (median dose) | 502 mg/kg (rat, subcutaneous) |
| NIOSH | DJ7V32DF6O |
| PEL (Permissible) | PEL (Permissible) of 11Α,17Α-Dihydroxyprogesterone: Not established |
| REL (Recommended) | 0.1–0.2 mg/kg |
| Related compounds | |
| Related compounds |
11α-Hydroxyprogesterone 17α-Hydroxyprogesterone |
